Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method
Treament | Trials | |||||
---|---|---|---|---|---|---|
Demonstrated or suggested benefit | Inconclusive results | Uncertain results | Safety results | |||
anti-inflammatory therapies | none | inconclusive results for: death D28; deaths; deaths (time to event analysis only); hospitalization; mechanical ventilation; mechanical ventilation (time to event analysis only); ICU admission; severe COVID-19 occurrence | - | - | ||
corticosteroids | none | - | - | - | ||
Immunostimulants drugs | none | - | suggested 61 % decrease in hospitalization or death but the degree if certainty is unassessable suggested 61 % decrease in hospitalization but the degree if certainty is unassessable | - | ||
Immunosuppressants drugs | none | inconclusive results for: radiologic improvement (14-day); serious adverse events | - | - | ||
Apilimod | 0 | - | - | - | - | |
inhaled corticosteroids | 0 | - | - | - | - | |
Kinase inhibitors | 0 | - | - | - | - | |
leflunomide | 0 | - | - | - | - | |
meplazumab | 0 | - | - | - | - | |
pirfenidone | 0 | - | - | - | - | |
Polyinosinic-Polycytidylic Acid | 0 | - | - | - | - | |
sargramostim | 0 | - | - | - | - | |
statins | 0 | - | - | - | - | |
thymosin | 0 | - | - | - | - |